Integrated Filing — IndAS



General information about company

Scrip Code 508869
NSE Symbol APOLLOHOSP
MSEI Symbol NOTLISTED
ISIN INE437A01024
Name of company APOLLO HOSPITALS ENTERPRISE LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 10-02-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 16-01-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Third quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 10-02-2026   14:45:00
End date and time of board meeting 10-02-2026   17:40:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-10-2025 01-04-2025
B Date of end of reporting period 31-12-2025 31-12-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 6,47,740.00 18,62,300.00
Other income 5,280.00 14,770.00
Total income 6,53,020.00 18,77,070.00
2 Expenses
(a) Cost of materials consumed 74,460.00 2,26,340.00
(b) Purchases of stock-in-trade 2,66,310.00 7,44,330.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (2,530.00) (3,310.00)
(d) Employee benefit expense 74,900.00 2,22,830.00
(e) Finance costs 11,260.00 33,050.00
(f) Depreciation, depletion and amortisation expense 21,920.00 65,170.00
(f) Other Expenses
1 Other Expenses 1,38,070.00 3,96,280.00
Total other expenses 1,38,070.00 3,96,280.00
Total expenses 5,84,390.00 16,84,690.00
3 Total profit before exceptional items and tax 68,630.00 1,92,380.00
4 Exceptional items (1,920.00) (1,920.00)
5 Total profit before tax 66,710.00 1,90,460.00
6 Tax expense
7 Current tax 14,700.00 43,330.00
8 Deferred tax 1,870.00 5,480.00
9 Total tax expenses 16,570.00 48,810.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 50,140.00 1,41,650.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 1,490.00 3,480.00
16 Total profit (loss) for period 51,630.00 1,45,130.00
17 Other comprehensive income net of taxes (20.00) 6,250.00
18 Total Comprehensive Income for the period 51,610.00 1,51,380.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 50,230.00 1,41,230.00
Total profit or loss, attributable to non-controlling interests 1,400.00 3,900.00
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 50,220.00 1,47,470.00
Total comprehensive income for the period attributable to owners of parent non-controlling interests 1,390.00 3,910.00
21 Details of equity share capital
Paid-up equity share capital 7,190.00 7,190.00
Face value of equity share capital 5 5
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 34.94 98.23
Diluted earnings (loss) per share from continuing operations 34.94 98.23
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 34.94 98.23
Diluted earnings (loss) per share from continuing and discontinued operations 34.94 98.23
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-10-2025 01-04-2025
Date of end of reporting period 31-12-2025 31-12-2025
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 a) Healthcare services 3,22,530.00 9,41,640.00
2 b) Retail health and diagnostics 46,680.00 1,37,580.00
3 c) Digital health and pharmacy distribution 2,82,750.00 7,95,990.00
4 d) Others 0.0013 0.0039
Total Segment Revenue 6,52,090.00 18,75,600.00
Less: Inter segment revenue 4,350.00 13,300.00
Revenue from operations 6,47,740.00 18,62,300.00
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 a) Healthcare services 62,430.00 1,81,580.00
2 b) Retail health and diagnostics 1,170.00 3,240.00
3 c) Digital health and pharmacy distribution 10,800.00 26,310.00
4 d) Others 210.00 (470.00)
Total Profit before tax 74,610.00 2,10,660.00
i. Finance cost 11,260.00 33,050.00
ii. Other Unallocable Expenditure net off Unallocable income 5,280.00 14,770.00
Profit before tax 58,070.00 1,62,840.00
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 a) Healthcare services 13,66,510.00 13,66,510.00
2 b) Retail health and diagnostics 1,39,920.00 1,39,920.00
3 c) Digital health and pharmacy distribution 3,19,370.00 3,19,370.00
4 d) Others 2,640.00 2,640.00
Total Segment Asset 18,28,440.00 18,28,440.00
Un-allocable Assets 4,16,210.00 4,16,210.00
Net Segment Asset 22,44,650.00 22,44,650.00
4 Segment Liabilities
Segment Liabilities
1 a) Healthcare services 4,35,590.00 4,35,590.00
2 b) Retail health and diagnostics 1,16,360.00 1,16,360.00
3 c) Digital health and pharmacy distribution 94,250.00 94,250.00
4 d) Others 1,820.00 1,820.00
Total Segment Liabilities 6,48,020.00 6,48,020.00
Un-allocable Liabilities 5,86,550.00 5,86,550.00
Net Segment Liabilities 12,34,570.00 12,34,570.00
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-10-2025 01-04-2025
B Date of end of reporting period 31-12-2025 31-12-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 'Remeasurement gains / (losses) on defined benefit plan (90.00) (400.00)
2 'Equity instruments through other comprehensive income 0.00 7,450.00
Total Amount of items that will not be reclassified to profit and loss (90.00) 7,050.00
2 Income tax relating to items that will not be reclassified to profit or loss (30.00) 950.00
3 Amount of items that will be reclassified to profit and loss
1 Exchange differences in translating the financial statements of foreign operations 40.00 150.00
Total Amount of items that will be reclassified to profit and loss 40.00 150.00
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income (20.00) 6,250.00





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Unaudited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 DELOITTE HASKINS & SELLS LLP Yes 31-07-2027